Lastly, we hold that this paper is the first report for the identification of a prognostic factor CDH2 and for showing the presence of a subtype with immune activation signature through the use of expression profiles of biopsy samples from ESCC patients who received definitive CRT. Here, CDH2 is linked to esophageal squamous cell carcinoma.